Anti-PD-L1 Immunotherapy Plus ABRAXANE ® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast ...

First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic triple negative ... These data demonstrate the potential role of ABRAXAN...